Render Target: STATIC
Render Timestamp: 2024-10-14T10:47:48.062Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-04-25 20:37:07.123
Product last modified at: 2024-06-07T08:00:16.152Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CTLA-4 (Ipilimumab Biosimilar) Human mAb #57924

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG1 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    CTLA-4 (Ipilimumab Biosimilar) Human mAb is a biosimilar antibody for Ipilimumab. Ipilimumab is a therapeutic human monoclonal antibody directed against CTLA-4, an immune checkpoint protein.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    CTLA-4 (Ipilimumab Biosimilar) Human mAb was confirmed to bind to its intended target protein CTLA-4 using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    CTLA-4 (Ipilimumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Ipilimumab is an antibody directed against the extracellular region of human CTLA-4.

    Background

    Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) is an Ig superfamily member that negatively regulates early T cell activation (1-4). The CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells (1,2). CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, which results in the downregulation of T cell activity (5). The activation of SHP-2 and PP2A downstream of CTLA-4 attenuates TCR signaling (6). Research studies indicate that CTLA4 knockout mice display lymphoproliferative disorders leading to early death, confirming the role of CTLA-4 as a negative regulator of T cells (7). Mutations in the corresponding CTLA4 gene are associated with multiple disorders, including insulin-dependent diabetes mellitus, Graves' disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, and type V autoimmune lymphoproliferative syndrome (8,9). Additional studies demonstrate that CTLA-4 blockade is an effective strategy for tumor immunotherapy (10-12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.